News
CHMP recommends Lynparza + abiraterone + prednisone or prednisolone for the treatment of adult patients with mCRPC in whom chemotherapy is not clinically indicated
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Lynparza
The marketing authorisation holder for this medicinal product is AstraZeneca AB.
The CHMP adopted a new indication as follows:Lynparza is indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with mCRPC in whom chemotherapy is not clinically indicated.
Condition: Prostate Cancer
Type: drug